about
Inhibition of hepatitis B viral entry by nucleic acid polymers in HepaRG cells and primary human hepatocytesDiscovery of naturally occurring transmissible chronic hepatitis B virus infection among Macaca fascicularis from Mauritius Island.PARP inhibition and the radiosensitizing effects of the PARP inhibitor ABT-888 in in vitro hepatocellular carcinoma models.Update on hepatocellular carcinoma breakthroughs: poly(ADP-ribose) polymerase inhibitors as a promising therapeutic strategy.Improved rolling circle amplification (RCA) of hepatitis B virus (HBV) relaxed-circular serum DNA (RC-DNA).Sodium taurocholate cotransporting polypeptide is the limiting host factor of hepatitis B virus infection in macaque and pig hepatocytes.Occult HBV infection in Morocco: from chronic hepatitis to hepatocellular carcinoma.Implementation of an in-house quantitative real-time polymerase chain reaction method for Hepatitis B virus quantification in West African countries.Anti-E1E2 antibodies status prior therapy favors direct-acting antiviral treatment efficacy.Development of a simple score based on HBeAg and ALT for selecting patients for HBV treatment in AfricaToll-like receptor 9 polymorphisms and Hepatitis B virus clearance in Moroccan chronic carriersDistribution of total DNA and cccDNA in serum and PBMCs may reflect the HBV immune status in HBsAg+ and HBsAg- patients coinfected or not with HIV or HCV[Prevention of liver fibrosis and liver cancer linked to hepatitis B virus in Africa: the Prolifica study]Alteration of splicing factors' expression during liver disease progression: impact on hepatocellular carcinoma outcomeIntegration of hepatitis B virus DNA into p21-activated kinase 3 (PAK3) gene in HepG2.2.15 cells
P50
Q33821878-D4CCE4DF-7DEC-46D6-A20A-A666C480902CQ34335676-7BA321CD-1767-4607-952F-CCB0B466152FQ35228413-4AED7148-1F9F-4AC0-B02B-C03BC7967679Q38129537-295762F4-B3E8-429B-A340-653D6776B5E5Q38395347-432851C0-E88B-453C-8BE7-0BEDE0237CFBQ38716558-88FF215F-659C-423B-9C0F-8B8BDA670728Q39139520-07C74F57-73E9-4610-8825-C5FA5B5CCA87Q40471393-B76254BD-8DBC-462B-9319-DC55D34FC389Q54253965-B55B7A15-A3F7-4B2A-BEA2-B784949DB5EFQ56336721-F19E3DE3-3A0F-4529-A39B-C2CB37CB8E3EQ59350601-DA566D89-59BE-4B0C-8B7F-14B5C0FFCEE3Q86344751-E4D9C2E1-86A4-4603-917A-95C01928D73DQ92206211-D3CA2583-D978-4E1F-BA8A-8404213AF477Q92364955-1A8C7831-67D7-4987-BE5C-0AA0B087815AQ92387780-49C5CF81-4F43-427C-B8DD-941630B029BC
P50
description
researcher ORCID ID = 0000-0002-7188-5489
@en
wetenschapper
@nl
name
Isabelle Chemin
@ast
Isabelle Chemin
@en
Isabelle Chemin
@es
Isabelle Chemin
@nl
type
label
Isabelle Chemin
@ast
Isabelle Chemin
@en
Isabelle Chemin
@es
Isabelle Chemin
@nl
prefLabel
Isabelle Chemin
@ast
Isabelle Chemin
@en
Isabelle Chemin
@es
Isabelle Chemin
@nl
P106
P31
P496
0000-0002-7188-5489